Clinical Trials
9 trialsNCT07142421 2025-08-26
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT07128693 2025-08-19
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT06426797 2024-05-23
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT06354530 2024-04-09
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Army Medical Center of PLA
Phase 2/3 Recruiting
NCT05866510 2023-05-19
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
Peking University
Phase 2 Unknown
NCT05322499 2022-04-11
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03387904 2021-09-02
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04813406 2021-03-24
Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Henan Provincial People's Hospital
Phase NA Unknown
NCT02649361 2019-06-05
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed